Skip to main content
Fig. 3 | The Journal of Headache and Pain

Fig. 3

From: Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study

Fig. 3

mTOQ-6 Mean Change From Baseline to Week 4. A Mean change from baseline to week 4 in mTOQ-6 total score and B in mTOQ-6 item scores. mTOQ-6, 6-item Migraine Treatment Optimization Questionnaire. aLimited to patients with both baseline and post-baseline mTOQ-6 data. **P < .01, #P = .0053 vs placebo

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us